Summary of brivanib and total radioactivity plasma PK parameters in patients
n = 4. Statistics are presented as follows: geometric mean (coefficient of variation percent) for Cmax, AUC, AUC ratios, CL/F, and CLR; median (minimum, maximum) for Tmax; and mean ± SD for t1/2.
| Parameter | Brivanib | Plasma TRA |
|---|---|---|
| Cmax (ng/ml) | 6146 (15) | 9350 (19) |
| Tmax (h) | 1 (0.5, 1) | 1 (0.5, 1.9) |
| AUC0–inf (ng · h/ml) | 45,892 (9) | 203,823 (20) |
| t1/2 (h) | 13.8 ± 2.8 | 105 ± 27 |
| CL/F (ml/min) | 14.7 (10) | 4 (21) |
| CLR (l/h) | 0.001 (42) | 0.496 (44) |
| Plasma AUC(brivanib)/AUC(TRA) | 0.23 (13) | |
| TRA blood AUC/plasma AUC ratio | 0.52 (32) | |